Benign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2025

Summary

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

According to APO Research, the global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.

The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Company

Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Benign Prostatic Hyperplasia (BPH) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2020-2031)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2020-2031)
2.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2020-2031)
2.3 Benign Prostatic Hyperplasia (BPH) Drugs by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Alpha-Blocker
2.3.3 Phosphodiesterase Type-5 Inhibitors
2.3.4 Others
2.4 Benign Prostatic Hyperplasia (BPH) Drugs by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospitals
2.4.3 Drugstores
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Manufacturers (2020-2025)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue of Manufacturers (2020-2025)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2020-2025)
3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
3.8 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Established Date
3.9 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Eli Lilly
4.1.1 Eli Lilly Company Information
4.1.2 Eli Lilly Business Overview
4.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.1.5 Eli Lilly Recent Developments
4.2 GlaxoSmithKline
4.2.1 GlaxoSmithKline Company Information
4.2.2 GlaxoSmithKline Business Overview
4.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.2.5 GlaxoSmithKline Recent Developments
4.3 Astellas Pharma
4.3.1 Astellas Pharma Company Information
4.3.2 Astellas Pharma Business Overview
4.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.3.5 Astellas Pharma Recent Developments
4.4 Sanofi
4.4.1 Sanofi Company Information
4.4.2 Sanofi Business Overview
4.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.4.5 Sanofi Recent Developments
4.5 Pfizer
4.5.1 Pfizer Company Information
4.5.2 Pfizer Business Overview
4.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.5.5 Pfizer Recent Developments
4.6 Abbott
4.6.1 Abbott Company Information
4.6.2 Abbott Business Overview
4.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.6.5 Abbott Recent Developments
4.7 Allergan
4.7.1 Allergan Company Information
4.7.2 Allergan Business Overview
4.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.7.5 Allergan Recent Developments
4.8 TEVA
4.8.1 TEVA Company Information
4.8.2 TEVA Business Overview
4.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.8.5 TEVA Recent Developments
4.9 Mylan
4.9.1 Mylan Company Information
4.9.2 Mylan Business Overview
4.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.9.5 Mylan Recent Developments
4.10 Novartis
4.10.1 Novartis Company Information
4.10.2 Novartis Business Overview
4.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.10.5 Novartis Recent Developments
4.11 Merck
4.11.1 Merck Company Information
4.11.2 Merck Business Overview
4.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
4.11.5 Merck Recent Developments
5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Scenario by Region
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2020-2031
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2020-2025
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2026-2031
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2020-2031
5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2020-2025
5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2026-2031
5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
5.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
5.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
5.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
5.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
5.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
5.7.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
5.7.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
5.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2031)
6.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2031) & (M Units)
6.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2031)
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2031)
6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2020-2031)
6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2020-2031)
7 Segment by Application
7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2031)
7.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2031) & (M Units)
7.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2031)
7.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2031)
7.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2031)
7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
8.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
8.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
9 Global Benign Prostatic Hyperplasia (BPH) Drugs Analyzing Market Dynamics
9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
9.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
9.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings